Trial · NCT00589290

Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage

NCT00589290, Phase 2, Completed, National Cancer Institute (NCI); results first posted 2012-05-30

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage. Trials, record NCT00589290. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00589290

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage
NCT number: NCT00589290
Status: Completed
Phases: Phase 2
Enrollment: 41 participants, actual
Lead sponsor: National Cancer Institute (NCI)
Conditions: Thymoma, Thymic Carcinoma
Interventions: Belinostat (PDX101)
First posted: 2008-01-09
Last updated: 2015-09-30
Results first posted: 2012-05-30

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Participants With a Partial Response	25.5 months	Response is defined by the Response Evaluation Criteria in Solid Tumor (RECIST). Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. For additional details about the RECIST criteria see the protocol Link module.
Primary	Chromosomal Gains or Losses in Comparative Genomic Hydridization in Thymoma and Thymic Cancer	46 months	Utilize a patients tumor tissue to determine if there is any correlation between chromosomal gains or losses in comparative genomic hybridization in thymoma and thymic carcinomas and clinical outcomes.
Secondary	Number of Participants With Adverse Events	26 months	Here are the number of participants with adverse events. For a detailed list of adverse events see the adverse event module.

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Participants With a Partial Response	25.5 months		Participants	NUMBER
SECONDARY	Number of Participants With Adverse Events	26 months		Participants	NUMBER
PRIMARY	Chromosomal Gains or Losses in Comparative Genomic Hydridization in Thymoma and Thymic Cancer	46 months	Unpublished data from Dr. Giaccone's lab does not reveal an association between these parameters and outcomes in patients with thymic malignancies. Hence we do not plan to perform analyses for these outcome measures and there is no known negative clinical implications associated with this.

Source ClinicalTrials.gov

Results by group3

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Number of Participants With a Partial Response	Thymoma Patients	2	2.3 to 25.9	Participants
Number of Participants With a Partial Response	Thymic Patients	0	0 to 19.4	Participants
Number of Participants With Adverse Events	Belinostat	41		Participants

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Belinostat Treatment	41
Overall Study	COMPLETED	Belinostat Treatment	40
Overall Study	NOT COMPLETED	Belinostat Treatment	1

Source ClinicalTrials.gov

Adverse events130

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anemia	Blood and lymphatic system disorders	Belinostat Treatment	27	41	54
other	Palpitations	Cardiac disorders	Belinostat Treatment	1	41	1
other	Sinus tachycardia	Cardiac disorders	Belinostat Treatment	6	41	8
other	Abdominal distension	Gastrointestinal disorders	Belinostat Treatment	2	41	2
other	Abdominal pain	Gastrointestinal disorders	Belinostat Treatment	1	41	1
other	Abdominal pain	Gastrointestinal disorders	Belinostat Treatment	2	41	2
other	Constipation	Gastrointestinal disorders	Belinostat Treatment	11	41	14
other	Diarrhea	Gastrointestinal disorders	Belinostat Treatment	6	41	7
other	Dyspepsia	Gastrointestinal disorders	Belinostat Treatment	1	41	2
other	Nausea	Gastrointestinal disorders	Belinostat Treatment	23	41	61

1 to 10 of 130Source ClinicalTrials.gov

See all 130 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Belinostat Treatment
Total, other adverse events	Belinostat Treatment	41	41
Total, serious adverse events	Belinostat Treatment	6	41

Source ClinicalTrials.gov

Papers4

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
15725919	BACKGROUND	PubMed
16891859	BACKGROUND	PubMed
17570676	BACKGROUND	PubMed
21502553	RESULT	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Thymoma Patients vs Thymic Patients: Number of Participants With a Partial Response

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00589290

GET https://conductscience.org/api/trials/v1/NCT00589290/events?page=2

API reference For AI assistants